B
텔콘RF제약
200230KOSDAQ의약품 제조업55.5 / 100
Reference Date: 2026-04-13
Financial Score24.0 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 20.0% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Telcon RF Pharmaceuticals primarily manufactures connectors and cable assemblies for wireless communication equipment, expanding into optical solutions and 5G FTTA (Fiber-To-The-Antenna) technology to strengthen its global market position. In the pharmaceutical and biotech sector, the company produces various dosage forms using KGMP-certified facilities and invests in new drug development.
Number of Employees
133people
Average Salary
55.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 14.804.0Point
PBR
0.40Industry Average 1.047.0Point
Half of industry avg (excellent)
ROE
-11.91Industry Average 4.420.0Point
Well below industry avg
Debt Ratio
1.46Industry Average 11.988.0Point
Half of industry avg (excellent)
Trend 2023~20255.0 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲9.1% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲505.6% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -8.4% (declining, 3yr)
Detailed News Sentiment
3 totalPositive 0Neutral 0Negative 0
- Neutral
- Neutral
- Neutral
Detailed Momentum
52-week position1.0Point
Near 52w low (0%, downtrend)
Current 628Won52-week high 3,80052-week low 618
1-month return0.0Point
1m -20.00% (strong drop)
Volume trend6.0Point
Volume increasing
Detailed Disclosure
8 totalPositive 1Neutral 7Negative 0
- Neutral주요사항보고서(감자결정)2026-04-08
- Neutral주주총회소집결의 (임시주주총회)2026-04-07
- Neutral주주명부폐쇄기간또는기준일설정2026-04-07
- Positive주요사항보고서(유상증자결정)2026-04-07
- Neutral주식매수선택권부여에관한신고2026-03-27